On October 14, 2021 Taiwan Liposome Company reported In light of the long term planning and realization of the shareholders’ interest and in order to improve the performance of the operations by taking advantage of the efficiency and size of the overseas listing and equity financing, Taiwan Liposome Company, Ltd.’s ("TLC") board resolved on July 5 and August 4, 2021 to enter into the share swap agreement and its first amendment with Woods Investment Co., Ltd. ("Woods Investment") pursuant to which TLC and Woods Investment would conduct a share swap and Woods Investment would acquire 100% of TLC shares by issuance of series B special shares and cash as consideration ("Share Swap"). This Share Swap was completed on October 8, 2021. The following timelines are for your Information:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(I). Share Swap Timelines (unless otherwise indicated, all dates and times are Taiwan local times)

Last trading date on NASDAQ September 28, 2021 (New York time)
Termination of listing of ADS on NASDAQ September 30, 2021 (New York time)
Last trading date of common shares September 29, 2021
Suspension of trading of common shares September 30, 2021 to October 8, 2021
Last update of shareholders registry October 1, 2021
Book closure period October 4, 2021 to October 8, 2021
Share Swap record date October 8, 2021
Termination of listing on Taipei Exchange October 8, 2021

(Filing, Taiwan Liposome Company, OCT 14, 2021, https://www.sec.gov/Archives/edgar/data/1722890/000119312521299062/d208712dex112.htm?utm_source=chatgpt.com [SID1234670483])